;PMID: 7851843
;source_file_937.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..39] = [t:0..39]
;1)sentence:[e:45..173] = [t:45..173]
;2)section:[e:177..240] = [t:177..240]
;3)section:[e:244..314] = [t:244..314]
;4)sentence:[e:318..737] = [t:318..737]
;5)sentence:[e:738..818] = [t:738..818]
;6)sentence:[e:819..982] = [t:819..982]
;7)sentence:[e:983..1117] = [t:983..1117]
;8)section:[e:1121..1165] = [t:1121..1165]

;section 0 Span:0..39
;Fundam Clin Pharmacol. 1994;8(4):373-8.
(SEC
  (FRAG (NNP:[0..6] Fundam) (NNP:[7..11] Clin) (NNP:[12..21] Pharmacol)
        (.:[21..22] .) (CD:[23..27] 1994) (CC:[27..30] ;8-LRB-)
        (CD:[30..32] 4-RRB-) (CD:[32..36] :373) (::[36..37] -) (CD:[37..39] 8.)))

;sentence 1 Span:45..173
;The effect of different calcium antagonists and a calcium agonist on the 
;metabolism of propranolol by isolated rat hepatocytes.
;[69..76]:substance:"calcium"
;[77..88]:substance:"antagonists"
;[95..102]:substance:"calcium"
;[103..110]:substance:"agonist"
;[133..144]:substance:"propranolol"
(SENT
  (NP-HLN
    (NP (DT:[45..48] The) (NN:[49..55] effect))
    (PP (IN:[56..58] of)
      (NP
        (NP (JJ:[59..68] different) (NN:[69..76] calcium)
            (NNS:[77..88] antagonists))
        (CC:[89..92] and)
        (NP (DT:[93..94] a) (NN:[95..102] calcium) (NN:[103..110] agonist))))
    (PP (IN:[111..113] on)
      (NP
        (NP (DT:[114..117] the) (NN:[119..129] metabolism))
        (PP (IN:[130..132] of)
          (NP (NN:[133..144] propranolol)))
        (PP (IN:[145..147] by)
          (NP (VBN:[148..156] isolated) (NN:[157..160] rat)
              (NNS:[161..172] hepatocytes)))))
    (.:[172..173] .)))

;section 2 Span:177..240
;Vercruysse I, Vermeulen AM, Belpaire FM, Massart DL, Dupont AG.
(SEC
  (FRAG (NNP:[177..187] Vercruysse) (NNP:[188..189] I) (,:[189..190] ,)
        (NNP:[191..200] Vermeulen) (NNP:[201..203] AM) (,:[203..204] ,)
        (NNP:[205..213] Belpaire) (NNP:[214..216] FM) (,:[216..217] ,)
        (NNP:[218..225] Massart) (NNP:[226..228] DL) (,:[228..229] ,)
        (NNP:[230..236] Dupont) (NNP:[237..239] AG) (.:[239..240] .)))

;section 3 Span:244..314
;Department of Pharmacology, Vrije Universiteit Brussel (VUB), Belgium.
(SEC
  (FRAG (NNP:[244..254] Department) (IN:[255..257] of)
        (NNP:[258..270] Pharmacology) (,:[270..271] ,) (NNP:[272..277] Vrije)
        (NNP:[278..290] Universiteit) (NNP:[291..298] Brussel)
        (-LRB-:[299..300] -LRB-) (NNP:[300..304] VUB-RRB-) (,:[304..305] ,)
        (NNP:[306..313] Belgium) (.:[313..314] .)))

;sentence 4 Span:318..737
;The influence of the dihydropyridine calcium entry blockers nicardipine, 
;amlodipine, nifedipine, isradipine and of the dihydropyridine calcium entry 
;promotor BAY K 8644 on the disappearance rate of propranolol by isolated rat 
;hepatocytes was compared to the effect of diltiazem and verapamil, two 
;non-dihydropyridine calcium channel blockers and known inhibitors of hepatic 
;cytochrome P450 mixed function oxidases.
;[339..362]:substance:"dihydropyridine calcium"
;[369..377]:substance:"blockers"
;[378..389]:substance:"nicardipine"
;[392..402]:substance:"amlodipine"
;[404..414]:substance:"nifedipine"
;[416..426]:substance:"isradipine"
;[438..461]:substance:"dihydropyridine calcium"
;[469..477]:substance:"promotor"
;[478..488]:substance:"BAY K 8644"
;[518..529]:substance:"propranolol"
;[589..598]:substance:"diltiazem"
;[603..612]:substance:"verapamil"
;[619..646]:substance:"non-dihydropyridine calcium"
;[655..663]:substance:"blockers"
;[674..684]:substance:"inhibitors"
;[697..712]:cyp450:"cytochrome P450"
;[728..736]:substance:"oxidases"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[318..321] The) (NN:[322..331] influence))
      (PP
        (PP (IN:[332..334] of)
          (NP
            (NP (DT:[335..338] the)
               (NN:[339..354] dihydropyridine) (NN:[355..362] calcium)
              (NN:[363..368] entry) (NNS:[369..377] blockers))
            (NP (NN:[378..389] nicardipine) (,:[389..390] ,)
                (NN:[392..402] amlodipine) (,:[402..403] ,)
                (NN:[404..414] nifedipine) (,:[414..415] ,)
                (NN:[416..426] isradipine))))
        (CC:[427..430] and)
        (PP (IN:[431..433] of)
          (NP
            (NP (DT:[434..437] the)
               (NN:[438..453] dihydropyridine) (NN:[454..461] calcium)
              (NN:[462..467] entry) (NN:[469..477] promotor))
            (NP (NN:[478..481] BAY) (NN:[482..483] K) (CD:[484..488] 8644)))))
      (PP (IN:[489..491] on)
        (NP
          (NP (DT:[492..495] the) (NN:[496..509] disappearance)
              (NN:[510..514] rate))
          (PP (IN:[515..517] of)
            (NP (NN:[518..529] propranolol)))))
      (PP (IN:[530..532] by)
        (NP (VBN:[533..541] isolated) (NN:[542..545] rat)
            (NNS:[547..558] hepatocytes))))
    (VP (VBD:[559..562] was)
      (VP (VBN:[563..571] compared)
        (NP-1 (-NONE-:[571..571] *))
        (PP-CLR (TO:[572..574] to)
          (NP
            (NP (DT:[575..578] the) (NN:[579..585] effect))
            (PP (IN:[586..588] of)
              (NP
                (NP (NN:[589..598] diltiazem) (CC:[599..602] and)
                    (NN:[603..612] verapamil))
                (,:[612..613] ,)
                (NP
                  (NP (CD:[614..617] two)
                    (NML (AFX:[619..622] non) (HYPH:[622..623] -)
                         (NN:[623..638] dihydropyridine))
                    (NML (NN:[639..646] calcium) (NN:[647..654] channel))
                    (NNS:[655..663] blockers))
                  (CC:[664..667] and)
                  (NP
                    (NP (VBN:[668..673] known) (NNS:[674..684] inhibitors))
                    (PP (IN:[685..687] of)
                      (NP (JJ:[688..695] hepatic)
                        (NML (NN:[697..707] cytochrome) (NN:[708..712] P450))
                        (NML (VBN:[713..718] mixed) (NN:[719..727] function))
                        (NNS:[728..736] oxidases)))))))))))
    (.:[736..737] .)))

;sentence 5 Span:738..818
;All compounds dose-dependently  inhibited the disappearance rate of
;propranolol.
;[742..751]:substance:"compounds"
;[806..817]:substance:"propranolol"
(SENT
  (S
    (NP-SBJ (DT:[738..741] All) (NNS:[742..751] compounds))
    (ADVP (NN:[752..756] dose) (HYPH:[756..757] -) (RB:[757..768] dependently))
    (VP (VBD:[770..779] inhibited)
      (NP
        (NP (DT:[780..783] the) (NN:[784..797] disappearance)
            (NN:[798..802] rate))
        (PP (IN:[803..805] of)
          (NP (NN:[806..817] propranolol)))))
    (.:[817..818] .)))

;sentence 6 Span:819..982
;Nicardipine and isradipine were  more potent in inhibiting the disappearance
;rate of propranolol than the other  dihydropyridines and than diltiazem and
;verapamil.
;[819..830]:substance:"Nicardipine"
;[835..845]:substance:"isradipine"
;[904..915]:substance:"propranolol"
;[932..948]:substance:"dihydropyridines"
;[958..967]:substance:"diltiazem"
;[972..981]:substance:"verapamil"
(SENT
  (S
    (NP-SBJ (NN:[819..830] Nicardipine) (CC:[831..834] and)
            (NN:[835..845] isradipine))
    (VP (VBD:[846..850] were)
      (ADJP-PRD
        (ADJP (RBR:[852..856] more) (JJ:[857..863] potent))
        (PP-1 (-NONE-:[863..863] *ICH*)))
      (PP (IN:[864..866] in)
        (S-NOM
          (NP-SBJ (-NONE-:[866..866] *))
          (VP (VBG:[867..877] inhibiting)
            (NP
              (NP (DT:[878..881] the) (NN:[882..895] disappearance)
                  (NN:[896..900] rate))
              (PP (IN:[901..903] of)
                (NP (NN:[904..915] propranolol)))))))
      (PP-1
        (PP (IN:[916..920] than)
          (NP (DT:[921..924] the) (JJ:[925..930] other)
              (NNS:[932..948] dihydropyridines)))
        (CC:[949..952] and)
        (PP (IN:[953..957] than)
          (NP (NN:[958..967] diltiazem) (CC:[968..971] and)
              (NN:[972..981] verapamil)))))
    (.:[981..982] .)))

;sentence 7 Span:983..1117
;The inhibitory effect of  nicardipine on the disappearance rate of
;propranolol was not stereoselective and  was not influenced by age.
;[1009..1020]:substance:"nicardipine"
;[1050..1061]:substance:"propranolol"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[983..986] The) (JJ:[987..997] inhibitory) (NN:[998..1004] effect))
      (PP (IN:[1005..1007] of)
        (NP (NN:[1009..1020] nicardipine)))
      (PP (IN:[1021..1023] on)
        (NP
          (NP (DT:[1024..1027] the) (NN:[1028..1041] disappearance)
              (NN:[1042..1046] rate))
          (PP (IN:[1047..1049] of)
            (NP (NN:[1050..1061] propranolol))))))
    (VP
      (VP (VBD:[1062..1065] was) (RB:[1066..1069] not)
        (ADJP-PRD (JJ:[1070..1085] stereoselective)))
      (CC:[1086..1089] and)
      (VP (VBD:[1091..1094] was) (RB:[1095..1098] not)
        (VP (VBN:[1099..1109] influenced)
          (NP-1 (-NONE-:[1109..1109] *))
          (PP (IN:[1110..1112] by)
            (NP-LGS (NN:[1113..1116] age))))))
    (.:[1116..1117] .)))

;section 8 Span:1121..1165
;PMID: 7851843 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1121..1125] PMID) (::[1125..1126] :) (CD:[1127..1134] 7851843)
        (NN:[1135..1136] -LSB-) (NNP:[1136..1142] PubMed) (::[1143..1144] -)
        (NN:[1145..1152] indexed) (IN:[1153..1156] for)
        (NNP:[1157..1165] MEDLINE-RSB-)))
